文献速递肿瘤 PET/CT

全身[68Ga]Ga-PSMA-11 PET/CT在根治性前列腺切除术后PSA<0.2 ng/mL的早期复发前列腺癌患者中检出率优于短轴视野[68Ga]Ga-PSMA-11 PET/CT

The superior detection rate of total-body [68Ga]Ga-PSMA-11 PET/CT compared to short axial field-of-view [68Ga]Ga-PSMA-11 PET/CT for early recurrent prostate cancer patients with PSA < 0.2 ng/mL after radical prostatectomy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-03-22

本研究将80例根治性前列腺切除术后生化复发且PSA<0.2 ng/mL的患者与80例基线特征匹配的短轴视野(SAFOV)[68Ga]Ga-PSMA-11 PET/CT患者进行比较。全身[68Ga]Ga-PSMA PET/CT检出率为73.75%,显著高于SAFOV的43.75%(P<0.001),且图像质量更优并导致治疗方案显著改变。

要点

  • PSA<0.2 ng/mL的生化复发患者中,全身[68Ga]Ga-PSMA PET/CT检出率73.75%,显著高于SAFOV的43.75%(P<0.001)。
  • 全身[68Ga]Ga-PSMA PET/CT在早期和延迟显像中的图像质量均优于SAFOV [68Ga]Ga-PSMA-11 PET/CT。
  • 与SAFOV相比,全身[68Ga]Ga-PSMA PET/CT导致治疗方案发生显著改变。

核心结论

  • 在PSA<0.2 ng/mL的生化复发患者中,全身[68Ga]Ga-PSMA-11 PET/CT检出率显著高于SAFOV [68Ga]Ga-PSMA-11 PET/CT,并导致治疗方案显著改变。

研究设计与样本

  • 80例PSA<0.2 ng/mL的生化复发患者接受全身[68Ga]Ga-PSMA-11 PET/CT,按基线特征与另80例接受SAFOV [68Ga]Ga-PSMA-11 PET/CT的患者匹配。
  • 采用卡方检验和分层分析比较两种PET/CT的检出率,并基于主观评分和客观参数评估图像质量。
  • 客观参数包括肝和臀大肌的SUVmax、SUVmean、SUV标准差和信噪比。

主要发现

  • 全身[68Ga]Ga-PSMA PET/CT在早期和延迟显像中的图像质量均优于SAFOV [68Ga]Ga-PSMA-11 PET/CT。
  • 全身[68Ga]Ga-PSMA PET/CT对PSA<0.2 ng/mL生化复发患者的检出率为73.75%,显著高于SAFOV [68Ga]Ga-PSMA-11 PET/CT的43.75%(P<0.001)。
  • 与SAFOV [68Ga]Ga-PSMA-11 PET/CT相比,全身[68Ga]Ga-PSMA PET/CT导致治疗方案发生显著改变。

关键数值与推荐

  • 全身[68Ga]Ga-PSMA PET/CT检出率73.75% vs SAFOV [68Ga]Ga-PSMA-11 PET/CT检出率43.75%(P<0.001)。

临床怎么用

  • 对于根治性前列腺切除术后PSA<0.2 ng/mL的生化复发患者,全身[68Ga]Ga-PSMA-11 PET/CT较SAFOV [68Ga]Ga-PSMA-11 PET/CT检出率更高,并可显著改变治疗方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: [68Ga]Ga-PSMA PET imaging has been extensively utilized for the detection of biochemical recurrence (BCR) in prostate cancer. However, the detection rate declines to merely 10-40% when PSA levels are < 0.2 ng/mL employing short axial field-of-view (SAFOV) PET. Prior studies exhibited superior detection rates with total-body [68Ga]Ga-PSMA-11 PET compared to SAFOV [68Ga]Ga-PSMA-11 PET in BCR patients with PSA > 0.2 ng/mL. Nevertheless, the diagnostic utility of total-body [68Ga]Ga-PSMA-11 PET for BCR patients when PSA is < 0.2 ng/mL remains unclear. This study aimed to assess whether total-body [68Ga]Ga-PSMA-11 PET/CT could improve the detection rate compared to SAFOV [68Ga]Ga-PSMA-11 PET/CT in BCR patients with PSA < 0.2 ng/mL. METHODS: Eighty BCR patients with PSA < 0.2 ng/mL underwent total-body [68Ga]Ga-PSMA-11 PET/CT. These patients were matched by baseline qualities to another 80 patients who received SAFOV [68Ga]Ga-PSMA-11 PET/CT. The detection rates of total-body [68Ga]Ga-PSMA-11 PET/CT and SAFOV [68Ga]Ga-PSMA-11 PET/CT were compared utilizing a chi-square test and stratified analysis. Image quality of total-body [68Ga]Ga-PSMA PET/CT and SAFOV [68Ga]Ga-PSMA-11 PET/CT was assessed based on subjective scoring and objective parameters. The objective parameters measured were SUVmax, SUVmean, standard deviation (SD) of SUV, and signal-to-noise ratio (SNR) of liver and gluteus maximus. RESULTS: The image quality of total-body [68Ga]Ga-PSMA PET/CT was superior to that of SAFOV [68Ga]Ga-PSMA-11 PET/CT in both early and delayed scans. The detection rate of total-body [68Ga]Ga-PSMA PET/CT for BCR patients with PSA < 0.2 ng/mL was significantly higher than that of SAFOV [68Ga]Ga-PSMA-11 PET/CT (73.75% vs. 43.75%, P < 0.001). Total-body [68Ga]Ga-PSMA PET/CT resulted in noteworthy modifications to the treatment regimen when contrasted with SAFOV [68Ga]Ga-PSMA-11 PET/CT. CONCLUSIONS: In BCR patients with PSA < 0.2 ng/mL, total-body [68Ga]Ga-PSMA-11 PET/CT not only demonstrated a significantly higher detection rate compared to SAFOV [68Ga]Ga-PSMA-11 PET/CT but also led to significant alterations in treatment regimens.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wang Y, Dong L, Zhao H, et al. The superior detection rate of total-body [68Ga]Ga-PSMA-11 PET/CT compared to short axial field-of-view [68Ga]Ga-PSMA-11 PET/CT for early recurrent prostate cancer patients with PSA < 0.2 ng/mL after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2024. PMID: 38514483. doi:10.1007/s00259-024-06674-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。